ClinicalTrials.gg
Not yet recruitingNCT07814443RLS/CKD-aPUpdated Sep 11, 2026

The Effect of Acupressure on Restless Legs Syndrome and Pruritus in Patients Undergoing Hemodialysis

An interventional study of Vibration Assisted Acupressure in Restless Leg Syndrome (RLS), sponsored by University of Baghdad. Not yet recruiting at 1 site in Iraq. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by University of Baghdad · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial aims to evaluate the effect of combined traditional and paraspinal acupressure on restless legs syndrome and pruritus among patients undergoing hemodialysis. Participants will be randomly assigned to either an intervention group receiving the acupressure intervention in addition to routine hemodialysis care or a control group receiving routine care only. The severity of restless legs syndrome and pruritus will be assessed at predetermined time points using validated assessment tools. The study aims to determine whether the combined acupressure intervention is effective in reducing restless legs syndrome and pruritus symptoms in patients undergoing hemodialysis

Read the detailed description

Participants allocated to the intervention group will receive combined traditional and paraspinal acupressure in addition to routine hemodialysis care. The intervention will involve stimulation of selected acupressure points using a vibration acupressure device.

The paraspinal component will include selected thoracic and lumbar points (BL13, BL17, BL23, BL24, and BL25) and will be applied before the hemodialysis session. Traditional peripheral acupressure points, including SP6, SP10, ST36, LI11, LR3, and BL57, will be stimulated during the hemodialysis session.The intervention will be administered according to a standardized protocol regarding point localization, application technique, duration, and frequency to ensure consistency among participants. Participants will be observed during the intervention for any discomfort or adverse events.

Participants allocated to the control group will continue to receive routine hemodialysis care without the acupressure intervention during the study period.

Restless legs syndrome severity and pruritus severity will be evaluated using validated instruments at three predetermined assessment time points. The collected data will be used to examine changes in symptoms over time and differences between the two study groups.

02

Conditions studied

  • Restless Leg Syndrome (RLS)
03

In context

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

This study's planned enrollment of 70 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.

Browse Restless Legs Syndrome studies →

Lead sponsor

University of Baghdad is the lead sponsor of 170 studies on the registry; 69 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients more than 18 years old on hemodialysis treatment for more than 2 sessions per week.
  2. The patients on hemodialysis for more than 3 months
  3. The patients who complain of restless leg syndrome and pruritus.
  4. RLS diagnosis meeting the diagnostic criteria defined by the International Restless Legs Syndrome Study Group (IRLSSG).
  5. At least moderate RLS symptoms (IRLS - total score ≥ 11)
  6. Patients who score more than five on the 5D Pruritus scale.
  7. Patient with a history of pruritus for more than 3 months.

Exclusion criteria

Exclusion Criteria

  1. Patients with impaired skin integrity.
  2. Patients with skin lesions in areas involved in acupressure therapy.
  3. Patients with neurological deficits as perception of pain, may differ from other patients.
  4. Patients with a (BMI) of more than > 30 kg/m².
  5. Patients with .
  6. Patients with Jaundice.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    intervention group (Vibration assisted acupressure)

    Participants in this group will receive vibration-assisted acupressure using an acupressure device applied to selected acupoints in addition to routine hemodialysis care. The intervention will be administered according to the study protocol to evaluate its effects on restless legs syndrome and pruritus among patients undergoing

    Other: Vibration Assisted Acupressure

  • No intervention
    CONTROL GROUP

    Participants will receive routine hemodialysis care without the acupressure intervention

Interventions

  • OtherVibration Assisted Acupressure

    Vibration-assisted acupressure will be applied to selected traditional and paraspinal acupoints using a handheld vibration device. The intervention is designed to reduce the severity of restless legs syndrome and pruritus in patients undergoing hemodialysis. It will be administered according to a predefined intervention protocol in addition to routine hemodialysis care

06

What researchers measure

Primary outcomes

  1. Change in Restless Legs Syndrome Severity Assessed by the International Restless Legs Syndrome Study Group Rating Scale (IRLS)

    The questionnaire consisted of 10 items, each of which had a scale ranging from 0 (no impact) to 4 (very severe impact). RLS severity was defined as mild (0-10 points), moderate (11-20 points), severe (21-30 points), or very severe (31-40 points).

    Time frame: Baseline (before intervention), 1 month after initiation of the intervention, and 2 months after initiation of the intervention

  2. Change in Pruritus Severity Assessed by the 5-D Itch Scale

    Pruritus severity will be assessed using the 5-D Itch Scale, which evaluates five dimensions of itching: duration, degree, direction, disability, and distribution. The total score ranges from 5 to 25, with higher scores indicating greater severity and impact of pruritus

    Time frame: Baseline (before intervention), 1 month after initiation of the intervention, and 2 months after initiation of the intervention

07

Study locations

1 site
  • Al-Hussien Hemodialysis center
    Dhi-Qar, Dhi Qar 64001, Iraq
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07814443
Responsible party
Alaa Kadhim Abdul-Hameed (PHD student, University of Baghdad) — Principal investigator
First posted
Sep 11, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Alaa Kadhim Abdul-Hameed, Assist lecturer
Contact
alaa-kadhim@utq.edu.iq
+9647763497862
Hakima Shaker Hassan, Assist prof
study director · College of Nursing/ University of Baghdad

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion